GigaGen CEO David Johnson to Present on Development of Recombinant Polyclonal Therapies for Infectious Disease at 10th Annual PEGS Summit Europe

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., Founder and Chief Executive Officer, will present on the development of highly diverse, functional antibodies for infectious disease utilizing Surge technology at the 10th Annual Protein & Antibody Engineering Summit (PEGS) in Europe. Dr. Johnson’s invited podium presentation is titled “Microfluidics and Genomics for Polyclonal and Monoclonal Antibody Drugs for Infectious Disease” and will take place during the Engineering Antibodies conference at 11:15 a.m. GMT on November 13, 2018, at the Libson Congress Center in Libson, Portugal.

Read the full press release.